BILL ANALYSIS �
ACR 131
Page 1
Date of Hearing: August 9, 2012
ASSEMBLY COMMITTEE ON RULES
Nancy Skinner, Chair
ACR 131 (Galgiani) - As Introduced: March 19, 2012
SUBJECT : Chronic Obstructive Pulmonary Disease Awareness.
SUMMARY : Designates November 2012 as Chronic Obstructive
Pulmonary Disease (COPD) Awareness Month in California; and,
encourages public officials and the citizens of California to
increase awareness of the symptoms of, and the methods of
preventing, COPD. Specifically, this resolution makes the
following legislative findings:
1)COPD, also known as chronic bronchitis and emphysema, is the
third leading cause of death in the United States; and, its
prevalence and death rate is rising.
2)COPD is a chronic and progressive disease that impacts an
estimated 24 million Americans each year; and, many patients
suffering with COPD are not diagnosed until they have reached
an advanced state which often includes a disabling degree of
lung dysfunction.
3)A diagnostic test for COPD, known as spirometry, is available
for office use, allowing early diagnosis of COPD; and, early
diagnosis and management of COPD can lead to an improved
quality of life and self-sufficiency for patients who received
publicly funded benefits, including Medi-Cal.
4)The "Healthy People 2020" project of the Centers of Disease
Control and Prevention and the National Institutes of Health
concludes that primary care physicians are in a key position
to provide optimal care to patients with COPD; and, these
physicians need to be trained in the latest methods for
diagnosing and treating the disease.
5)The California COPD Coalition has developed a comprehensive
plan to address COPD in the state, entitled the "Strategic
Plan to Address COPD in California," which outlines six goal
areas, including the following: prevention, quality of care,
public health infrastructure and advocacy, surveillance,
research, and public education awareness.
ACR 131
Page 2
FISCAL EFFECT : Unknown
REGISTERED SUPPORT / OPPOSITION :
Support
Boehringer Ingelheim Pharmaceuticals, Inc.
AstraZeneca Pharmaceuticals LP
Opposition
None on file.
Analysis Prepared by : Nicole Willis / RLS. / (916) 319-2800